{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:48:59Z","timestamp":1753274939783},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.bulcan.2018.05.018","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T05:14:50Z","timestamp":1541481290000},"page":"S40-S51","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["Seconde allogreffe\u00a0: recommandations de la Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"106","author":[{"given":"Nabil","family":"Yafour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Anne","family":"Couturier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Azarnoush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Girault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hermet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavroula","family":"Masouridi Levrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascaline","family":"Etancelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Sirvent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Poir\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2018.05.018_bib0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2009.10.023","article-title":"Relapse after allogeneic hematopoietic cell therapy","volume":"16","author":"van den Brink","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.bulcan.2018.05.018_bib0375","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2018.05.018_bib0380","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bmt.2009.300","article-title":"Management of relapse after allo-SCT for AML and the role of second transplantation","volume":"44","author":"Savani","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.018_bib0385","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/ehm.10.32","article-title":"Relapse after allogeneic stem cell transplantation","volume":"3","author":"Barrett","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.018_bib0390","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.retram.2017.06.001","article-title":"How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome","volume":"65","author":"Yafour","year":"2017","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"10.1016\/j.bulcan.2018.05.018_bib0395","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/imt.15.100","article-title":"Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation","volume":"8","author":"Stamouli","year":"2016","journal-title":"Immunotherapy"},{"issue":"12s","key":"10.1016\/j.bulcan.2018.05.018_bib0400","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.bulcan.2017.05.009","article-title":"[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]","volume":"104","author":"Yafour","year":"2017","journal-title":"Bull Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2018.05.018_bib0405","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bulcan.2018.05.018_bib0410","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/ejh.12647","article-title":"High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation","volume":"96","author":"De Freitas","year":"2016","journal-title":"Eur J Haematol"},{"issue":"31","key":"10.1016\/j.bulcan.2018.05.018_bib0415","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.018_bib0420","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/bmt.2014.300","article-title":"Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT","volume":"50","author":"Sauer","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2018.05.018_bib0425","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","article-title":"Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Poon","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2018.05.018_bib0430","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the acute leukemia working party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bulcan.2018.05.018_bib0435","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"issue":"11S","key":"10.1016\/j.bulcan.2018.05.018_bib0440","article-title":"[Management of graft failure and erythroblastopenia in patients undergoing allogeneic hematopoietic stem cell transplantation: guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]","volume":"103","author":"Cornillon","year":"2016","journal-title":"Bull Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2018.05.018_bib0445","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/bmt.2015.193","article-title":"Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 10\u00a0years","volume":"50","author":"Andreola","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.018_bib0450","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2141.1991.tb08083.x","article-title":"Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working party","volume":"79","author":"Barrett","year":"1991","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bulcan.2018.05.018_bib0455","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbmt.2010.02.013","article-title":"Second unrelated donor hematopoietic cell transplantation for primary graft failure","volume":"16","author":"Schriber","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.018_bib0460","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.13650","article-title":"Second allogeneic stem cell transplant for aplastic anaemia: a retrospective study by the Severe Aplastic Anaemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"171","author":"Cesaro","year":"2015","journal-title":"Br J Haematol"},{"issue":"11S","key":"10.1016\/j.bulcan.2018.05.018_bib0465","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2018.05.018_bib0470","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2018.05.018_bib0475","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2018.05.018_bib0480","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2018.05.018_bib0485","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bulcan.2018.05.018_bib0490","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"year":"2017","series-title":"second allograft for relapsed or refractory acute myeloid leukemia after first allogeneic stem cell transplantation. A Study on behalf of the SFGM-TC. Oral presentation","author":"Couturier","key":"10.1016\/j.bulcan.2018.05.018_bib0495"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.018_bib0500","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2011.06.010","article-title":"EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure","volume":"18","author":"Rezvani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.018_bib0505","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/bmt.2015.221","article-title":"Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes","volume":"51","author":"Vrhovac","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2018.05.018_bib0510","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbmt.2015.11.012","article-title":"Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the Grupo Espanol de Trasplante Hematopoyetico","volume":"22","author":"Orti","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.bulcan.2018.05.018_bib0515","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","article-title":"Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change","volume":"31","author":"Christopeit","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.018_bib0520","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bmt.2015.186","article-title":"Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT","volume":"50","author":"Ruutu","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2018.05.018_bib0525","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bmt.2008.255","article-title":"Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant","volume":"42","author":"Shaw","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2018.05.018_bib0530","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbmt.2014.10.006","article-title":"Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes","volume":"21","author":"Duncan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2018.05.018_bib0535","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/j.bbmt.2016.06.027","article-title":"Refining the Role of Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia as Novel Therapies Emerge","volume":"22","author":"El Fakih","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2018.05.018_bib0540","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","article-title":"Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"19","author":"Poon","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"10.1016\/j.bulcan.2018.05.018_bib0545","first-page":"30574","article-title":"Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"S1083-8791","author":"Introna","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2018.05.018_bib0550","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2018.05.018_bib0555","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.exphem.2017.04.002","article-title":"Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators","volume":"51","author":"Lepretre","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bulcan.2018.05.018_bib0560","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.leukres.2017.05.013","article-title":"Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"59","author":"Gu","year":"2017","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.bulcan.2018.05.018_bib0565","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbmt.2007.04.013","article-title":"High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-hodgkin lymphoma","volume":"14","author":"Bloor","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2018.05.018_bib0570","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bbmt.2011.02.009","article-title":"Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome","volume":"17","author":"Wudhikarn","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.bulcan.2018.05.018_bib0575","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.018_bib0580","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjh.12013","article-title":"Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting","volume":"159","author":"Klyuchnikov","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bulcan.2018.05.018_bib0585","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","article-title":"Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant","volume":"34","author":"Eapen","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2018.05.018_bib0590","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/bmt.2014.83","article-title":"Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation","volume":"49","author":"Tischer","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.018_bib0595","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2141.2000.01851.x","article-title":"Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle (SFGM)","volume":"108","author":"Michallet","year":"2000","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.018_bib0600","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1993.11.2.304","article-title":"Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens","volume":"11","author":"Radich","year":"1993","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.018_bib0605","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbmt.2011.06.015","article-title":"Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC","volume":"18","author":"Bay","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2018.05.018_bib0610","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.bbmt.2010.06.009","article-title":"Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants","volume":"16","author":"Hill","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.018_bib0615","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbmt.2009.01.009","article-title":"A retrospective review of the outcome after second or subsequent allogeneic transplantation","volume":"15","author":"Kedmi","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.bulcan.2018.05.018_bib0620","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3324\/haematol.12798","article-title":"Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation","volume":"93","author":"Platzbecker","year":"2008","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bulcan.2018.05.018_bib0625","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/sj.bmt.1703389","article-title":"Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation","volume":"29","author":"Wolff","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.bulcan.2018.05.018_bib0630","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.bbmt.2008.05.005","article-title":"Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis","volume":"14","author":"Rondon","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.018_bib0635","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.13650","article-title":"Second allogeneic stem cell transplant for aplastic anaemia: a retrospective study by the Severe Aplastic Anaemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"171","author":"Cesaro","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.bulcan.2018.05.018_bib0640","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.bbmt.2007.07.006","article-title":"Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure","volume":"13","author":"Chewning","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2018.05.018_bib0645","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.1111\/j.1399-0012.2010.01324.x","article-title":"Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure","volume":"25","author":"Remberger","year":"2011","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2018.05.018_bib0650","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.bmt.1705882","article-title":"Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection","volume":"41","author":"Byrne","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2018.05.018_bib0655","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ajh.24111","article-title":"Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure","volume":"90","author":"Lund","year":"2015","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.bulcan.2018.05.018_bib0660","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/bmt.2011.249","article-title":"The role of HLA antibodies in allogeneic SCT: is the \u201ctype-and-screen\u201d strategy necessary not only for blood type but also for HLA?","volume":"47","author":"Yoshihara","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2018.05.018_bib0665","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.bmt.1705072","article-title":"Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3\u00a0days of G-CSF identifies long-term responders","volume":"36","author":"Bittencourt","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2018.05.018_bib0670","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.bbmt.2013.11.034","article-title":"CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies","volume":"20","author":"Klyuchnikov","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2018.05.018_bib0675","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/bmt.2014.5","article-title":"Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning","volume":"49","author":"Askaa","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2018.05.018_bib0680","first-page":"935","article-title":"Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation","volume":"91","author":"Larocca","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bulcan.2018.05.018_bib0685","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.bbmt.2017.03.019","article-title":"Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation","volume":"23","author":"Ghobadi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.018_bib0690","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/14653240600735784","article-title":"CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation","volume":"8","author":"Oyekunle","year":"2006","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.bulcan.2018.05.018_bib0695","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.bbmt.2014.05.016","article-title":"CD34\u00a0selected cells for the treatment of poor graft function after allogeneic stem cell transplantation","volume":"20","author":"Stasia","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2018.05.018_bib0700","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s00432-015-2027-x","article-title":"Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation","volume":"141","author":"Haen","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.05.018_bib0705","first-page":"331","article-title":"Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON)","volume":"87","author":"Munoz","year":"2002","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.018_bib0710","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00277-016-2599-9","article-title":"Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia","volume":"95","author":"Menon","year":"2016","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.bulcan.2018.05.018_bib0715","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/pbc.25866","article-title":"Role of second transplantation for children with acute myeloid leukemia following posttransplantation relapse","volume":"63","author":"Taga","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2018.05.018_bib0720","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/bmt.2016.360","article-title":"Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the societe Francophone de greffe de moelle et de therapie cellulaire (SFGM-TC)","volume":"52","author":"Roux","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2018.05.018_bib0725","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bmt.2016.224","article-title":"Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience","volume":"52","author":"Willasch","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2018.05.018_bib0365","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/bmt.2015.153","article-title":"Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia","volume":"50","author":"Kudo","year":"2015","journal-title":"Bone Marrow Transplant"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118302832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118302832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T20:01:49Z","timestamp":1549656109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118302832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0007455118302832"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.05.018","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seconde allogreffe\u00a0: recommandations de la Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}